Phaseline

Companies › Thomas Advanced Medical

Thomas Advanced Medical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Infectious disease; next expected readout Jul 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PrimePro™/PrimeMSK™
Mesenchymal stem cells (MSCs) - cell-based regenerative therapy
–Phase 1Autoimmune DiseasesJul 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04684602PrimePro™/PrimeMSK™Phase 1Autoimmune DiseasesInfectious diseaseJul 2030

From the company's SEC filings

Complete response letters from FDA

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.